Screener
BioMarin Pharmaceuticals BMRN Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: BioMarin Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001048477-26-000016
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchase of intangible assets | (5,433) | (266) |
| Acquisition of Amicus, net of cash acquired | (5,067,630) | — |
| Other | 4,966 | — |
| Net cash used in investing activities | (4,376,351) | (40,830) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from exercises of awards under equity incentive plans | 6,655 | 7,707 |
| Taxes paid related to net share settlement of equity awards | (39,504) | (51,089) |
| Payments of contingent consideration | — | — |
Item 1. Financial Statements
FAQ
- What is BioMarin Pharmaceuticals's investing cash flow?
- BioMarin Pharmaceuticals (BMRN) reported investing cash flow of -$5.1B in Q2 2026.
- How has BioMarin Pharmaceuticals's investing cash flow changed year-over-year?
- BioMarin Pharmaceuticals's investing cash flow decreased by 40416.8% year-over-year, from -$12.59M to -$5.1B.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about BioMarin Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude